# A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

> **NCT07062965** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 400 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** PF-07248144
- **DRUG:** Fulvestrant
- **DRUG:** Everolimus
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT07062965
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-05
- **Primary completion:** 2027-07-22
- **Final completion:** 2030-11-04
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07062965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07062965, "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.". Retrieved via AI Analytics 2026-08-09 from https://api.ai-analytics.org/clinical/NCT07062965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*